Matthew Angel - 26 May 2022 Form 3 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role
Interim President and CEO
Signature
/s/ Matthew Angel
Issuer symbol
ERNA
Transactions as of
26 May 2022
Transactions value $
$0
Form type
3
Date filed
01 Jun 2022, 17:00
Next filing
03 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ERNA Common Stock 909K 26 May 2022 Direct F1
holding ERNA Common Stock 2.58M 26 May 2022 See Footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 285,888 shares of common stock of Brooklyn ImmunoTherapeutics, Inc. (the "Issuer") held in escrow until July 16, 2022 to secure indemnification obligations to the Issuer in connection with the Issuer's acquisition of Novellus, Inc. from Novellus, LLC in July 2021, which was co-founded by Dr. Angel.
F2 Common stock is owned by Factor Bioscience, Inc., of which Dr. Angel owns approximately 64% of the outstanding equity.

Remarks:

See Exhibit 24.1 - Power of Attorney